Stephen S Gottlieb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6664939/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2000, 283, 1295.	7.4	1,193
2	HIV Infection and the Risk of Acute Myocardial Infarction. JAMA Internal Medicine, 2013, 173, 614.	5.1	1,074
3	Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction. New England Journal of Medicine, 1998, 339, 489-497.	27.0	936
4	Sex Differences in the Management of Coronary Artery Disease. New England Journal of Medicine, 1991, 325, 226-230.	27.0	847
5	Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. Journal of the American College of Cardiology, 2004, 43, 61-67.	2.8	822
6	Ventricular Dysfunction and the Risk of Stroke after Myocardial Infarction. New England Journal of Medicine, 1997, 336, 251-257.	27.0	561
7	Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure. Circulation, 1996, 94, 2793-2799.	1.6	530
8	The prognostic importance of different definitions of worsening renal function in congestive heart failure. Journal of Cardiac Failure, 2002, 8, 136-141.	1.7	512
9	Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure. Circulation, 2000, 102, 2222-2227.	1.6	446
10	Relationship between heart failure treatment and development of worsening renal function among hospitalized patients11Guest Editor for this manuscript was Peter M. Okin, MD, New York Hosptial-Cornell Medical Center, New York, NY American Heart Journal, 2004, 147, 331-338.	2.7	444
11	Cardiorenal Syndrome. Circulation, 2010, 121, 2592-2600.	1.6	421
12	The influence of age, gender, and race on the prevalence of depression in heart failure patients. Journal of the American College of Cardiology, 2004, 43, 1542-1549.	2.8	384
13	Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart Failure. New England Journal of Medicine, 1987, 317, 799-804.	27.0	378
14	BG9719 (CVT-124), an A ₁ Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy. Circulation, 2002, 105, 1348-1353.	1.6	348
15	Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. Journal of the American College of Cardiology, 1989, 13, 1534-1539.	2.8	342
16	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	2.8	338
17	Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure: Basis of a new physiologic approach to control of arrhythmia. American Journal of Medicine, 1986, 80, 23-29.	1.5	302
18	Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of cardiology, 1994, 24, 583-591.	2.8	274

#	Article	IF	CITATIONS
19	Effects of Exercise Training on Depressive Symptoms in Patients With Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2012, 308, 465-74.	7.4	239
20	Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: A randomized study. Journal of the American College of Cardiology, 1995, 26, 967-973.	2.8	236
21	Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. Journal of the American College of Cardiology, 2005, 45, 1051-1060.	2.8	225
22	Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era. JAMA Cardiology, 2017, 2, 536.	6.1	210
23	Metoprolol CR/XL in Female Patients With Heart Failure. Circulation, 2002, 105, 1585-1591.	1.6	207
24	Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial. Journal of the American College of Cardiology, 1994, 23, 943-950.	2.8	182
25	Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine. Circulation, 2004, 110, 1620-1625.	1.6	181
26	A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: A multicenter evaluation. American Heart Journal, 2002, 144, 834-839.	2.7	172
27	Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction. Circulation, 2007, 116, 49-56.	1.6	156
28	Activation of neurohumoral systems in postinfarction left ventricular dysfunction. Journal of the American College of Cardiology, 1993, 22, 390-398.	2.8	149
29	Effects of BG9719 (CVT-124), an A1-Adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. Journal of the American College of Cardiology, 2000, 35, 56-59.	2.8	147
30	The Effect of Coenzyme Q ₁₀ in Patients with Congestive Heart Failure. Annals of Internal Medicine, 2000, 132, 636.	3.9	146
31	Acute Endothelin A Receptor Blockade Causes Selective Pulmonary Vasodilation in Patients With Chronic Heart Failure. Circulation, 2000, 101, 2922-2927.	1.6	146
32	Depression is common and precludes accurate assessment of functional status in elderly patients with congestive heart failure. Journal of Cardiac Failure, 2000, 6, 300-305.	1.7	139
33	B-Type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. American Heart Journal, 2006, 152, 1071-1076.	2.7	135
34	Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia. American Journal of Cardiology, 2006, 97, 1064-1067.	1.6	129
35	The Adequacy of Laboratory Monitoring in Patients Treated With Spironolactone for Congestive Heart Failure. Journal of the American College of Cardiology, 2005, 46, 845-849.	2.8	122
36	HIV Infection and Cardiovascular Disease in Women. Journal of the American Heart Association, 2014, 3, e001035.	3.7	120

7

#	Article	IF	CITATIONS
37	Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. American Heart Journal, 2001, 142, 502-511.	2.7	115
38	Relation of Depression to Severity of Illness in Heart Failure (from Heart Failure And a Controlled) Tj ETQqO 0 0 103, 1285-1289.	rgBT /Over 1.6	lock 10 Tf 50 1 113
39	Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. Journal of the American College of Cardiology, 1990, 16, 827-831.	2.8	110
40	Effects of exercise training on peak performance and quality of life in congestive heart failure patients. Journal of Cardiac Failure, 1999, 5, 188-194.	1.7	107
41	A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure. American Heart Journal, 2007, 153, 868-873.	2.7	100
42	A Randomized, Controlled Trial of the Renal Effects of Ultrafiltration as Compared to Furosemide in Patients With Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2008, 14, 1-5.	1.7	100
43	Efficacy, safety and tolerability of ?-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. European Heart Journal, 2004, 25, 1300-1309.	2.2	97
44	What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?. Journal of the American College of Cardiology, 2005, 45, 252-259.	2.8	96
45	Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic ana nonischemic cardiomyopathy. American Journal of Cardiology, 1995, 75, 460-464.	1.6	94
46	Cardiac Calcitropes, Myotropes, andÂMitotropes. Journal of the American College of Cardiology, 2019, 73, 2345-2353.	2.8	93
47	Extracorporeal Ultrafiltration for FluidÂOverload in Heart Failure. Journal of the American College of Cardiology, 2017, 69, 2428-2445.	2.8	88
48	Tolerability of β-Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation, 2002, 105, 1182-1188.	1.6	87
49	Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. Journal of the American College of Cardiology, 1987, 10, 837-844.	2.8	84
50	Depression in Heart Failure: Biobehavioral Mechanisms. Heart Failure Clinics, 2011, 7, 23-38.	2.1	78
51	Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1177-1183.	2.8	78
52	Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: Analysis of the Cardiac Arrhythmia Suppression Trial. Journal of the American College of Cardiology, 1995, 25, 1250-1257.	2.8	76
53	The Effect of a Randomized Trial of Home Telemonitoring on Medical Costs, 30-Day Readmissions, Mortality, and Health-Related Quality of Life in a Cohort of Community-Dwelling Heart Failure Patients. Journal of Cardiac Failure, 2014, 20, 513-521.	1.7	75
54	Plasma leptin concentrations and energy expenditure in heart failure patients. Metabolism: Clinical and Experimental, 1997, 46, 450-453.	3.4	69

#	Article	IF	CITATIONS
55	The Erythrocyte Sedimentation Rate in Congestive Heart Failure. New England Journal of Medicine, 1991, 324, 353-358.	27.0	66
56	New York Heart Association functional class predicts exercise parameters in the current era. American Heart Journal, 2009, 158, S24-S30.	2.7	65
57	Hypoxia, Not the Frequency of Sleep Apnea, Induces Acute Hemodynamic Stress in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2009, 54, 1706-1712.	2.8	65
58	Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE120008193.	3.9	65
59	Skeletal Muscle Atrophy and Peak Oxygen Consumption in Heart Failure. American Journal of Cardiology, 1997, 79, 1267-1269.	1.6	63
60	The Acute Hemodynamic Effects of Right Ventricular Septal Pacing in Patients With Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 1997, 79, 679-681.	1.6	62
61	Effects of Sleep Apnea on Nocturnal Free Fatty Acids in Subjects with Heart Failure. Sleep, 2011, 34, 1207-1213.	1.1	61
62	Depression and Human Immunodeficiency Virus Infection Are Risk Factors for Incident Heart Failure Among Veterans. Circulation, 2015, 132, 1630-1638.	1.6	58
63	Energy expenditure and symptom severity in men with heart failure. American Journal of Cardiology, 1996, 77, 1250-1252.	1.6	57
64	Benefits and Risks of Anticoagulation Resumption Following Traumatic Brain Injury. JAMA Internal Medicine, 2014, 174, 1244.	5.1	57
65	Diuretics: Still the mainstay of treatment. Critical Care Medicine, 2008, 36, S89-S94.	0.9	48
66	Preoperative Endogenous Ouabain Predicts Acute Kidney Injury in Cardiac Surgery Patients*. Critical Care Medicine, 2013, 41, 744-755.	0.9	48
67	Effects of intravenous magnesium sulfate on arrhythmias in patients with congestive heart failure. American Heart Journal, 1993, 125, 1645-1650.	2.7	47
68	A Phase 2a doseâ€escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of <scp>BMS</scp> â€986231 in hospitalized patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 1321-1332.	7.1	47
69	Renal Effects of Adenosine A1-Receptor Antagonists in Congestive Heart Failure. Drugs, 2001, 61, 1387-1393.	10.9	45
70	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. Circulation, 2014, 130, 958-965.	1.6	41
71	Toward Genetics-Driven Early Intervention in Dilated Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	41
72	Loop Diuretic Prescription and 30-DayÂOutcomes in Older Patients WithÂHeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 669-679.	2.8	41

#	Article	IF	CITATIONS
73	Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. American Heart Journal, 1999, 138, 1158-1165.	2.7	40
74	High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. Journal of the American College of Cardiology, 1994, 23, 560-564.	2.8	38
75	The Characteristics and Prognostic Importance of NT-ProBNP Concentrations in Critically III Patients. American Journal of Medicine, 2007, 120, 1071-1077.	1.5	38
76	A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans. Journal of Personalized Medicine, 2018, 8, 11.	2.5	38
77	Renal Hemodynamic Effects of Serelaxin in Patients With Chronic Heart Failure. Circulation: Heart Failure, 2014, 7, 994-1002.	3.9	36
78	Comparative Assessment of Short-TermÂAdverse Events in Acute Heart Failure WithÂCystatin C andÂOther Estimates ofÂRenal Function. JACC: Heart Failure, 2015, 3, 40-49.	4.1	35
79	Trastuzumab-Induced Cardiomyopathy: Incidence and Associated Risk Factors in an Inner-City Population. Journal of Cardiac Failure, 2014, 20, 555-559.	1.7	34
80	Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. American Journal of Medicine, 1987, 82, 1119-1126.	1.5	33
81	The Effects of Diuresis on the Pharmacokinetics of the Loop Diuretics Furosemide and Torsemide in Patients with Heart Failure. American Journal of Medicine, 1998, 104, 533-538.	1.5	33
82	Changes in psychosocial distress in outpatients with heart failure with implantable cardioverter defibrillators. Heart and Lung: Journal of Acute and Critical Care, 2009, 38, 109-120.	1.6	33
83	Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. European Journal of Heart Failure, 2013, 15, 324-333.	7.1	33
84	Daily energy requirements in heart failure patients. Metabolism: Clinical and Experimental, 1997, 46, 1294-1298.	3.4	31
85	Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after acute myocardial infarctionâ^—â^—The views expressed in this article do not necessarily reflect the official position of the Health Care Financing Administration American Journal of Cardiology, 2001, 87, 823-826	1.6	31
86	Effect of metoprolol on absolute myocardial blood flow in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy. American Journal of Cardiology, 2002, 89, 1431-1434.	1.6	31
87	Adverse Hemodynamic and Clinical Effects of Encainide in Severe Chronic Heart Failure. Annals of Internal Medicine, 1989, 110, 505.	3.9	30
88	Renal response to Indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1992, 70, 890-893.	1.6	29
89	Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST]). American Heart Journal, 2010, 160, 649-654.	2.7	28
90	Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. Clinical Biochemistry, 2015, 48, 292-296.	1.9	28

#	Article	IF	CITATIONS
91	Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy. JAMA - Journal of the American Medical Association, 2022, 327, 454.	7.4	28
92	Economic Implications of Extended-Release Metoprolol Succinate for Heart Failure in the MERIT-HF Trial: A US Perspective of the MERIT-HF Trial. Journal of Cardiac Failure, 2005, 11, 647-656.	1.7	27
93	Association between depressive symptoms and fibrosis markers: The Cardiovascular Health Study. Brain, Behavior, and Immunity, 2010, 24, 229-235.	4.1	27
94	Sex, Digitalis, and the Sodium Pump. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2003, 3, 68-72.	3.4	27
95	Protein-energy malnutrition in patients with ischemic and nonischemicdilated cardiomyopathy and congestive heart failure. American Journal of Cardiology, 1994, 73, 908-910.	1.6	26
96	The impact of finally publishing a negative study: new conclusions about endothelin antagonists. Journal of Cardiac Failure, 2005, 11, 21-22.	1.7	25
97	Effect of Chronic Changes in Heart Rate on Congestive Heart Failure. Journal of Cardiac Failure, 2007, 13, 269-274.	1.7	25
98	The use of antiarrhythmic agents in heart failure: Implications of CAST. American Heart Journal, 1989, 118, 1074-1077.	2.7	24
99	Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized) Tj ETQq1 1 0.784	4314 rgBT 1.6	/Overlock 10
100	Breastfeeding, Cellular Immune Activation, andÂMyocardial Recovery inÂPeripartumÂCardiomyopathy. JACC Basic To Translational Science, 2019, 4, 291-300.	4.1	24
101	The Effects of Adenosine A1 Receptor Antagonism in Patients With Acute Decompensated Heart Failure and Worsening Renal Function: The REACH UP Study. Journal of Cardiac Failure, 2010, 16, 714-719.	1.7	22
102	Anger, hostility, and hospitalizations in patients with heart failure Health Psychology, 2017, 36, 829-838.	1.6	20
103	Impedance cardiography: More questions than answers. Current Heart Failure Reports, 2006, 3, 107-113.	3.3	19
104	Adenosine A1 antagonists and the cardiorenal syndrome. Current Heart Failure Reports, 2008, 5, 105-109.	3.3	19
105	Test-Retest Reliability of Assessment for Intraventricular Dyssynchrony by Tissue Doppler Imaging Echocardiographyâ€â€Conflicts of interest: Dr. Shorofsky is a consultant for Medtronic and Boston Scientific. Dr. Mehra is a consultant for Medtronic, Boston Scientific, and St. Jude Medical American Iournal of Cardiology, 2008, 101, 645-650.	1.6	19
106	How Medicare Part D Benefit Phases Affect Adherence with Evidenceâ€Based Medications Following Acute Myocardial Infarction. Health Services Research, 2013, 48, 1960-1977.	2.0	19
107	High Concordance Between Mental Stress–Induced and Adenosine-Induced Myocardial Ischemia Assessed Using SPECT in Heart Failure Patients: Hemodynamic and Biomarker Correlates. Journal of Nuclear Medicine, 2015, 56, 1527-1533.	5.0	19
108	Deleterious hemodynamic effects of lidocaine in severe congestive heart failure. American Heart Journal, 1989, 118, 611-612.	2.7	17

#	Article	IF	CITATIONS
109	Psychological stress and short-term hospitalisations or death in patients with heart failure. Heart, 2016, 102, 1820-1825.	2.9	17
110	Exploration of patients' readiness for an eHealth management program for chronic heart failure: a preliminary study. Journal of Cardiovascular Nursing, 2008, 23, 463-71.	1.1	17
111	The Effect of Dementia on Medication Use and Adherence Among Medicare Beneficiaries With Chronic Heart Failure. American Journal of Geriatric Pharmacotherapy, 2012, 10, 69-80.	3.0	15
112	Circulating T-Cell Subsets, Monocytes, and Natural Killer Cells in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study. Journal of Cardiac Failure, 2018, 24, 33-42.	1.7	15
113	Determinants of the renal response to ACE inhibition in patients with congestive heart failure. American Heart Journal, 1992, 124, 131-136.	2.7	14
114	Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology, 1993, 22, 963-967.	2.8	14
115	First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patient with heart failure: A double-blind, randomized, multicenter study. American Heart Journal, 1994, 128, 551-556.	2.7	14
116	Effect of Exposure to Evidenceâ€Based Pharmacotherapy on Outcomes After Acute Myocardial Infarction in Older Adults. Journal of the American Geriatrics Society, 2012, 60, 1854-1861.	2.6	14
117	How Should Subgroup Analyses Affect Clinical Practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Journal of Interventional Cardiac Electrophysiology, 2003, 7, 264-275.	1.0	13
118	Association of persistent and transient worsening renal function with mortality risk, readmissions risk, length of stay, and costs in patients hospitalized with acute heart failure. ClinicoEconomics and Outcomes Research, 2015, 7, 357.	1.9	13
119	Associations of perceived stress and state anger with symptom burden and functional status in patients with heart failure. Psychology and Health, 2019, 34, 1250-1266.	2.2	13
120	Acute electrophysiologic effects of amiodarone in patients with congestive heart failure. American Journal of Cardiology, 1995, 75, 1158-1161.	1.6	12
121	Hemodynamic effects of the class III antiarrhythmic drug, d-sotalol, in patients with congestive heart failure. American Journal of Cardiology, 1996, 78, 1411-1415.	1.6	12
122	Effects of BG9928, an Adenosine A1Receptor Antagonist, in Patients With Congestive Heart Failure. Journal of Clinical Pharmacology, 2011, 51, 899-907.	2.0	12
123	Hemodynamic and neurohormonal effects of quinidine in patients with severe left ventricular dysfunction secondary to coronary artery disease or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1991, 67, 728-731.	1.6	10
124	Prognostic importance of the length of ventricular tachycardia in patients with nonischemic congestive heart failure. American Heart Journal, 1995, 130, 489-493.	2.7	10
125	Acute Congestive Heart Failure in the Emergency Department. Cardiology Clinics, 2006, 24, 115-123.	2.2	10
126	Clinical Trial Design in Contemporary Device Studies in Heart Failure: Is There a Gold Standard?. Journal of Cardiac Failure, 2014, 20, 223-228.	1.7	10

#	Article	IF	CITATIONS
127	Observation of Patients Transitioned to an Oral Loop Diuretic Before Discharge and Risk of Readmission for Acute Decompensated Heart Failure. Journal of Cardiac Failure, 2017, 23, 746-752.	1.7	10
128	Impact of Mental Stress and Anger on Indices of Diastolic Function in Patients With Heart Failure. Journal of Cardiac Failure, 2020, 26, 1006-1010.	1.7	10
129	Management of Sleep Disordered Breathing in Patients with Heart Failure. Current Heart Failure Reports, 2018, 15, 123-130.	3.3	9
130	Renal Dysfunction and Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2021, 17, 357-367.	2.1	9
131	Robust gene expression with amplified RNA from biopsy-sized human heart tissue. Journal of Molecular and Cellular Cardiology, 2007, 42, 260-264.	1.9	8
132	Should we overcome the resistance to bioelectrical impedance in heart failure?. Expert Review of Medical Devices, 2020, 17, 785-794.	2.8	8
133	Comparative hemodynamic effects of mexiletine and quinidine in patients with severe left ventricular dysfunction. American Heart Journal, 1991, 122, 1368-1374.	2.7	7
134	Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: A class III antiarrhythmic agent without cardiodepressant effects. Journal of the American College of Cardiology, 1995, 26, 1679-1684.	2.8	7
135	Morbidity and Mortality Benefits of Reliable Instrumental Support. Journal of Cardiac Failure, 2007, 13, S164.	1.7	7
136	Theory and Fact. JACC: Heart Failure, 2017, 5, 327-328.	4.1	7
137	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008594.	3.9	7
138	Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis. Journal of Cardiac Failure, 2004, 10, 452-459.	1.7	6
139	Diuretics. Journal of the American College of Cardiology, 2011, 57, 2242-2243.	2.8	6
140	Abnormal Valsalva blood pressure response in dilated cardiomyopathy: Association with "pseudonormalization―of echocardiographic Doppler transmitral filling velocity pattern. American Heart Journal, 1993, 126, 1182-1186.	2.7	5
141	β-Blockers for heart failure. Current Opinion in Cardiology, 1994, 9, 295-300.	1.8	5
142	Characteristics of patients referred for cardiac transplantation: Implications for the donor organ shortage. American Heart Journal, 2000, 140, 857-861.	2.7	5
143	One Year Changes in Quality of Life for Heart Failure Patients in a Home Telemonitoring Program. Journal of Cardiac Failure, 2006, 12, S122.	1.7	5
144	Carpal Tunnel Syndrome and FutureÂAmyloidosis. Journal of the American College of Cardiology, 2019, 74, 24-25.	2.8	5

#	Article	IF	CITATIONS
145	Insomnia symptoms and biomarkers of monocyte activation, systemic inflammation, and coagulation in HIV: Veterans Aging Cohort Study. PLoS ONE, 2021, 16, e0246073.	2.5	5
146	Use of Outpatient Intravenous Calcitropes for Heart Failure in the United States. Journal of Cardiac Failure, 2021, 27, 1276-1279.	1.7	5
147	Are all Î ² -blockers the same for chronic heart failure?. Current Cardiology Reports, 2001, 3, 124-129.	2.9	4
148	Nuggets, Pearls, and Vignettes of Master Heart Failure Clinicians. Congestive Heart Failure, 2001, 7, 245-249.	2.0	4
149	A New Clinically Applicable Measure of FunctionalÂStatus in Patients With HeartÂFailure. JACC: Heart Failure, 2017, 5, 411-420.	4.1	4
150	Coenzyme Q_10 and Congestive Heart Failure. Annals of Internal Medicine, 2000, 133, 745.	3.9	4
151	The use of pacemakers as treatment for systolic dysfunction. Journal of Cardiac Failure, 1998, 4, 145-150.	1.7	3
152	Warfarin usage among elderly atrial fibrillation patients with traumatic injury, an analysis of United States Medicare feeâ€forâ€service enrollees. Journal of Clinical Pharmacology, 2015, 55, 25-32.	2.0	3
153	Cardiac resynchronization therapy for heart failure. New England Journal of Medicine, 2002, 347, 1803-4; author reply 1803-4.	27.0	3
154	Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 209-210.	1.6	2
155	Arrhythmias and sudden death in congestive heart failure. Current Opinion in Cardiology, 1989, 4, 368-371.	1.8	1
156	The hemodynamic actions of the antiarrhythmic agent ipazilide fumarate in patients with congestive heart failure. Clinical Pharmacology and Therapeutics, 1994, 56, 75-81.	4.7	1
157	New approaches to managing congestive heart failure. Current Opinion in Cardiology, 1995, 10, 282-287.	1.8	1
158	Exercise in the Geriatric Patient With Congestive Heart Failure. The American Journal of Geriatric Cardiology, 2001, 10, 264-269.	0.6	1
159	Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction. Current Heart Failure Reports, 2004, 1, 161-167.	3.3	1
160	Effects of Single IV Doses of BC9928, an Adenosine A1 Antagonist, in Patients with Heart Failure. Journal of Cardiac Failure, 2008, 14, S67-S68.	1.7	1
161	Acute Decompensated Heart Failure. Cardiology Clinics, 2012, 30, 665-671.	2.2	1
162	Walking the Line of Euvolemia. Journal of Cardiac Failure, 2014, 20, 623-624.	1.7	1

#	Article	IF	CITATIONS
163	Trajectories of Renal Function During Heart Failure Hospitalization: Beware the Bumpy Ride!. Journal of Cardiac Failure, 2019, 25, 875-876.	1.7	1
164	Beta blockade improves survival in patients with congestive heart failure. Current Treatment Options in Cardiovascular Medicine, 1999, 1, 101-103.	0.9	0
165	The Incidence of Right Ventricular Dysfunction Is Similar in Pulsatile and Continuous-Flow Left Ventricular Assist Devices. Journal of Cardiac Failure, 2006, 12, S49.	1.7	Ο
166	A Randomized, Controlled Trail of the Renal Effects of Ultrafiltration as Compared to Furosemide. Journal of Cardiac Failure, 2007, 13, S139.	1.7	0
167	UNLOAD Response to Letter to the Editor. Journal of Cardiac Failure, 2008, 14, 534.	1.7	Ο
168	Using and Misusing Statistics. Circulation: Heart Failure, 2012, 5, 135-136.	3.9	0
169	Congruity between Mental Stress-Induced and Adenosine-Induced Myocardial Ischemia Assessed Using SPECT in Heart Failure Patients. Journal of Cardiac Failure, 2014, 20, S18.	1.7	Ο
170	Effects of Acute and Chronic Stress on Heart Failure Functional Status, Hospitalization and Mortality. Journal of Cardiac Failure, 2014, 20, S97.	1.7	0
171	Surrogate Endpoints: Not the Real Thing. Journal of Cardiac Failure, 2016, 22, 761-762.	1.7	Ο
172	Diuretic Strategies and Renal Dysfunction in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 1049-1050.	4.1	0
173	Why Does the Journal Need a Guest Editor?. Journal of Cardiac Failure, 2018, 24, 541.	1.7	Ο
174	The Risks of Big Databases: Why Do Married People Drown in Kentucky?. Journal of Cardiac Failure, 2018, 24, 451-452.	1.7	0
175	Consider Everything When PrescribingÂSacubitril/Valsartan. Journal of the American College of Cardiology, 2020, 76, 1049-1050.	2.8	0
176	Beta-blockers post-MI: an example of age discrimination?. Postgraduate Medicine, 2002, 112, 28-33.	2.0	0